CHM for Female Stress Urinary Incontinence

NCT06855602 | Recruiting

• 1 other identifier: REC/23-24/0483
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This single-arm, open-label pilot clinical trial will test the hypothesis that S-2196, a Chinese herbal medicine formula, will show efficacy and safety in alleviating the amount and frequency of urinary incontinence in female individuals with stress urinary incontinence. All participants (n=15) will receive 1 week of screening, 2 weeks of intervention, and 1 week of follow-up.

Conditions

Stress Urinary Incontinence (SUI)

Keywords

stress urinary incontinence; female

Outcome Measures

Primary Outcomes (2)

• The change in the amount of urine leakage during the 1-hour standard pad test compared to the baseline (time point: the end of the 2nd week of treatment)

  The measurement of leakage volume follows the standardized 1-hour pad test protocol by the International Continence Society (ICS). The procedure includes the following steps: (1) Participants are required to void their bladder 2 hours before the test. (2) Upon start, participants will wear a pre-weighed pad and are instructed to drink 500 milliliters of water within 15 minutes. (3) Participants will walk for 30 minutes, including walking up and down one flight of stairs. (4) Participants will perform the following activities during the remaining time: sit down and stand up 10 times, cough vigorously 10 times, run in place for 1 minute, bend down to pick up an object from the floor 5 times, and wash hands under running water for 1 minute. (5)After completing these activities, the pad will be weighed again to calculate the leakage volume. 1g \< leakage volume ≤ 10g is classified as mild; 10g \< leakage volume ≤ 50g is classified as moderate; leakage volume \> 50g is defined as severe.

  Baseline, week2

• The change in the average daily frequency of urinary incontinence episode compared to the baseline (time point: the end of the 2nd week of treatment).

  The average daily frequency of urinary incontinence episodes (IEF) is calculated based on the number of incidences of urinary incontinence within a continuous 24-hour period, as recorded in the patient-reported electronic bladder diaries.

  Baseline, week 2

Secondary Outcomes (1)

• The Change in International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score compared to baseline (Time point: after 2 weeks of treatment)

  Baseline, week 2

Other Outcomes (3)

• Safety Outcome: adverse events

  Baseline, week 2, week 3

• Safety Outcome: Heart rate (beats per minute, bpm)

  Baseline, week 2, week 3

• Safety Outcome: Systolic and Diastolic Blood Pressure (millimeters of mercury, mmHg))

  Baseline, Week 2, Week 3

Study Arms (1)

Treatment group

EXPERIMENTAL

Chinese herbal medicine decoction

Drug: Chinese herbal medicine formula (S-2196)

Interventions

Chinese herbal medicine formula (S-2196) DRUG

During the 2-week intervention, all participants are required to take 150ml of S-2196 decoction (a Chinese herbal medicine formula containing four herbs) twice per day

Treatment group

Eligibility Criteria

• Age: 55 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females aged ≥55 years
• Meet the ICUD diagnostic criteria of stress urinary incontinence
• Measured urine leakage \>10g in the 1-hour standard pad test
• Understand and can follow written and verbal instructions in Chinese
• Able to independently use and complete the electronic diary during the 1-week screening period
• The subject is informed and voluntarily signs the informed consent form

You may not qualify if:

• Patients with other types of urinary incontinence, such as neurogenic urinary incontinence, urge urinary incontinence, and overflow urinary incontinence.
• Subjects with the following urogenital system diseases (vesicoureteral reflux, detrusor instability, congenital urethral abnormalities, urinary tract infection or hematuria indicated by routine urinalysis or urine culture, urogenital fistula, urethral diverticulum, bladder stones, urinary system tumors, abnormal vaginal bleeding, pelvic malignant tumors, uterine prolapse grade II or above).
• History of SUI surgery or complex urethral surgery, including previous transvaginal tension-free mid-urethral sling, anterior wall prolapse repair, urethral injection therapy, etc.
• Previous pelvic radiotherapy, radical surgery for pelvic malignant tumors, and pelvic floor surgery.
• Currently receiving or needing to continue treatment related to urinary incontinence, including pelvic floor muscle training, physical therapy, pessary, and medication.
• If using medications that affect urination during the screening period (including but not limited to thiazolidinediones, sodium-glucose cotransporter 2 inhibitors, anticholinergics, alpha- and beta-adrenergic receptor antagonists, alpha- and beta-adrenergic receptor agonists, diuretic antihypertensive drugs, antihistamines, M receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormonal drugs, neurotransmitter drugs, intestinal flora regulating drugs, etc.), and unable to maintain a stable dose during the study period; or if considering using the above medications during the study period but not using them during the screening period.
• Presence of neurological disorders (including but not limited to central nervous system injury, motor neuron disease, neurodegenerative diseases), diabetes, connective tissue diseases, mental disorders, hypertension (defined as long-term monitored systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), severe cardiovascular and cerebrovascular diseases, severe liver or kidney diseases.
• Combined with chronic cough diseases such as chronic obstructive pulmonary disease (COPD), gastrointestinal diseases affecting drug absorption, or other chronic diseases in an unstable state.
• History of adverse reactions to traditional Chinese medicine, or G6PD deficiency.
• Unable to complete exercises such as walking or climbing stairs.
• Deemed unsuitable for participation in this study by the researchers due to psychological or physical reasons.

Sponsors & Collaborators

• Hong Kong Baptist University: lead

Study Sites (1)

Hong Kong Baptist University

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Urinary Incontinence, Stress

Condition Hierarchy (Ancestors)

Urinary Incontinence; Urination Disorders; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

ZhaoXiang Bian, Prof.

CONTACT

85234116521; bzxiang@hkbu.edu.hk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: November 29, 2024
• First Posted: March 4, 2025
• Study Start: October 21, 2024
• Primary Completion: March 15, 2026
• Study Completion (Estimated): May 22, 2026
• Last Updated: November 20, 2025

Record last verified: 2025-02

Locations

HK (1)